Heart failure (HF) remains a major global health challenge affecting over 64 million individuals worldwide and is associated with substantial morbidity, mortality, and healthcare expenditure. Despite significant advances in cardiovascular medicine, HF continues to be a leading cause of hospitalization among older adults. Recent years have witnessed remarkable developments in pharmacological therapies, device-based interventions, digital health technologies, and personalized medicine approaches. Novel drug classes such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and soluble guanylate cyclase stimulators have significantly improved clinical outcomes. Furthermore, advances in cardiac resynchronization therapy, implantable hemodynamic monitoring systems, telemedicine, artificial intelligence, and regenerative medicine are transforming HF management. This review examines recent advances in heart failure diagnosis, treatment, monitoring, and prevention, highlighting their impact on patient outcomes and healthcare delivery. The study emphasizes the importance of multidisciplinary, patient-centered approaches in achieving optimal management and reducing the burden of heart failure globally.